TagsOncology 
Taking a New Approach to Dyslipidaemia

Early Insight to the Dyslipidaemia Pandemic Dyslipidaemia is defined as lipid imbalance affecting the low high-density lipoprotein cholesterol (HDL-C), elevated triglyceride (TG), high low-density lipoprotein cholesterol (LDL-C) and elevated total c...

Feb 8, 2024
EXKIVITY

EXKIVITY (mobocertinib) TAKEDA Indications: EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, ...

Feb 6, 2024
COLUMVI

COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...

Feb 6, 2024
Ground-breaking Delivery of Anti-cancer Drug Against Lymph Node Metastasis

Being spotted in multiple cancer types, lymph node (LN) metastasis literally is the symbol of dreadful patient outcomes, characterizing poor prognosis and shorter survival. Recent research has highlighted sentinel LNs as the gateway for haematogenou...

Feb 6, 2024
Turning RCC to Rejoice, Courage, and Care: A Review on the Management of Renal Cell Carcinoma and the Related Innovations

Renal cell carcinomas (RCCs) are the most common type of kidney cancer in adults and is prevalent in adult male aged between 60 and 70. Notably, clear cell RCC (ccRCC) is the most abundant subtype of RCC with the worse disease-specific survival as i...

Feb 6, 2024
Trodelvy

Trodelvy (sacituzumab govitecan) Gilead Presentation: Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial. Indications: Trodelvy is indicated for the treatment of adult patients wit...

Dec 18, 2023
Exkivity

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...

Jun 13, 2023
Cancer Cells Use Uridine-derived Ribose as Fuel when Starved

Pancreatic ductal adenocarcinoma (PDA) is called a silent killer, as it is often discovered late and has a high mortality rate. Its treatment-resistant and aggressive nature can be attributed to the tumour microenvironment, low vascularity, and meta...

Jun 13, 2023
The New Age of Colorectal Cancer

Existing Knowledge on Colorectal Cancer Colorectal cancer (CRC) is the third most common type of cancer and second most common cause of cancer-related deaths globally 1 . There were over 1.9 million new cases of CRC globally in 2020 with medium to h...

Jun 13, 2023
The Promising Fixed-duration Oral Regimen for Older and Unfit Patients with Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is a chronic lymphoproliferative disorder characterised by proliferation of monoclonal mature B-cells in peripheral blood, bone marrow, and secondary lymphoid tissues, such as spleen and lymph nodes 1 . The incide...

Jun 13, 2023
Hybrid Lecture on Management of Relapsed or Refractory Multiple Myeloma

The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...

Mar 17, 2022
Proven Benefits of IMiDs-based Regimen in Managing Multiple Myeloma

Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...

Dec 20, 2021